1Falk E.Why do plaque rupture[J]?Circulation,1992,86[Suppl Ⅲ]:Ⅲ30-Ⅲ42.
2Davues MJ. Stability two faces of coronary atherosclerosisthe paul Dudley white Lecture, 1995[J]. Circulation, 1996,94(8) :2013-2020.
3陈修 陈维洲 曾贵云.心血管药理学[M](第2版)[M].北京:人民卫生出版社,1998..
4Patronol C, Ciabattoni G, Pinca F, et al. Low dose aspirin and inhibition of thromhoxane B2 production in healthy subjects[J]. Thramb Res,1980,17(3) :317.
5Lopez-Farre A, Caramelo I, Esteven A, et al. Effect of aspiren platelet-ncutrphil interactions, Role of hitric oxide and ondothelin-1 [J]. Circulation, 1995,91 (7) : 2080-2088.
6Gaetano G. Pharmacology of antipatelet drugs[ A]. Macintyre DE, Garden JL, et al. Platelets in Biology and pathology Ⅲ [C]. Amsterdam :Elsevier Science Publication, 1987.515.
7Spranger M, Aspey BS, Harrison MJ, et al. Sex difference in antithrombotic effect of aspirin[J]. Stroke, 1989,20(1) :34.
8Collins R, Peto R, Bavgent C, et al. Collaborative overview of randomized trials of antiplatelet therapy-1 prevention of cleath myocardial infarction and stroke by prolonged antiplatelet therapy invrvous categories Antiplatelet Triahst Colcaboration[J]. Br Med J, 1994,308(6921 ) : 81-106.
10Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)[J].Lancet, 1996,348(9038) : 1329-1339.
二级参考文献55
1[1]OiNell W, Serruys P, Knudtson M, et al. For the EXCITE Trial Investigators. Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization.N Engl J Med, 2000; 342: 1316～1324.
2[2]The SYMPHONY Investigators. Comparison of sibrafiban with Aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet, 2000; 355: 337～345.
3[3]Cannon C, McCabe C, Wilcox R, et al. Oral glycoprotein IIb/IIIa inhibition with orofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation, 2000; 102: 149～156.
4[4]Al-Khadra A, Salem D, Rand W, et al. Antiplatelet agents and survival: a cohort analysis from the stidies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol, 1998; 31: 419～425.
5[5]Peterson J, Topol E, Sapp S, et al. Evaluation of the effects of Aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med, 2000; 109:371～377.
6[6]Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurolog Sci, 1996; 143:1～13.
7[7]Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus Aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev, 2000;2:CD001246.
8[8]Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous nvein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med, 1997;337:1726～1731.
9[9]CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus Aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996;348:1329～1339.
10[10]David JL, Limet R. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. T Hromb Haemost,1999;82:1417～1421.
